The current study aimed to develop long-acting protease-resistant GLP-1R agonists with the potential for administration in type 2 diabetes mellitus treatment by designing and computationally analyzing the fusion proteins of the native or protease-resistant mutant GLP-1 and an HSA-binding DARPin. Here, GCG is linked to diabetes mellitus.